文献速递区域麻醉与超声心胸血管麻醉疼痛医学

鞘内吗啡与胸椎旁阻滞用于胸腔镜手术的非劣效性随机对照试验

Comparison of intrathecal morphine versus thoracic paravertebral block for video-assisted thoracoscopic surgery: a randomized non-inferiority trial.
PubMed 文献 · Reg Anesth Pain Med · 2026-06-17

该前瞻性随机对照非劣效性试验纳入72例择期胸腔镜手术成人,比较鞘内吗啡与胸椎旁阻滞的镇痛效果。主要终点24小时静脉吗啡毫克当量中,鞘内吗啡组与胸椎旁阻滞组的中位差异为6.5 mg(95%CI 1至17;p=0.009),置信区间上限超过预设非劣效界值5.05 mg,非劣效性未成立。两组疼痛评分与恢复质量相似,但鞘内吗啡组补救镇痛更频繁。

要点

  • 鞘内吗啡在24小时静脉吗啡用量上未达到对胸椎旁阻滞的非劣效性。
  • 胸椎旁阻滞与更低的全身阿片类药物用量相关,疼痛结局相似。
  • 鞘内吗啡组补救镇痛比例更高(21/36 vs 12/36;p=0.033)。

核心结论

  • 鞘内吗啡对胸椎旁阻滞在24小时静脉吗啡毫克当量上未显示非劣效性,胸椎旁阻滞与更低的全身阿片用量相关,而疼痛结局相似。

研究设计与样本

  • 前瞻性、随机、对照、观察者盲法的非劣效性试验,72例择期胸腔镜手术成人按1:1随机至胸椎旁阻滞组(n=36)或鞘内吗啡组(n=36),符合方案集排除2例中转开胸后为70例。

主要发现

  • 24小时静脉吗啡毫克当量中位差异(鞘内吗啡减胸椎旁阻滞)在意向性分析为6.5 mg(95%CI 1至17;p=0.009),符合方案分析为9.0 mg(95%CI 2至18;p=0.002),两分析置信区间上限均超过5.05 mg非劣效界值。
  • 24小时和12小时静脉吗啡毫克当量个体数据均倾向胸椎旁阻滞,鞘内吗啡组补救镇痛更频繁(21/36 vs 12/36;p=0.033)。
  • 疼痛评分、恢复质量评分及首次阿片需求时间两组相似,无呼吸抑制发生。

关键数值与推荐

  • 预设非劣效界值为5.05 mg(24小时静脉吗啡毫克当量)。
  • 胸椎旁阻滞方案为0.25%布比卡因0.4 mL/kg加肾上腺素1:400,000;鞘内吗啡剂量为按理想体重5 mcg/kg。

临床怎么用

  • 对于胸腔镜手术,胸椎旁阻滞在减少全身阿片用量方面优于鞘内吗啡,尽管疼痛评分相似。
  • 选择鞘内吗啡时需考虑补救镇痛需求可能更高。

局限性

  • 样本量较小(随机72例),符合方案分析排除2例中转开胸。
  • 30天Clavien-Dindo I级事件组间有差异,但未观察到明显临床意义的安全信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although widely performed, video-assisted thoracoscopic surgery (VATS) is associated with significant postoperative pain. Thoracic paravertebral block (TPVB) is a guideline-favored regional technique, while intrathecal morphine (ITM) is a technically less demanding and more widely applicable neuraxial alternative. We hypothesized that ITM would provide analgesic efficacy non-inferior to TPVB in terms of 24-hour intravenous morphine milligram equivalents (IV-MME). METHODS: This was a prospective, randomized, controlled, observer-blinded non-inferiority trial. Adults undergoing elective VATS were randomized 1:1 to TPVB (0.25% bupivacaine, 0.4 mL/kg+epinephrine 1:400,000) or ITM (5 mcg/kg based on ideal body weight). The primary endpoint was 24-hour IV-MME (intraoperative opioids excluded). Secondary endpoints included 12-hour IV-MME, pain (Numeric Rating Scale at rest/activity), rescue analgesia, time to first opioid demand, 15-item Quality of Recovery, safety (postoperative nausea/vomiting, pruritus, respiratory depression), and 30-day complications. The prespecified non-inferiority margin was 5.05 mg. Analyses followed intention-to-treat with per-protocol sensitivity. RESULTS: Of 82 screened, 72 were randomized (ITM n=36; TPVB n=36); 2 TPVB conversions to thoracotomy were excluded from the per-protocol set (n=70). For the primary endpoint, the median difference (ITM-TPVB) in 24-hour IV-MME was 6.5 mg (95% CI 1 to 17; p=0.009) in intention-to-treat and 9.0 mg (95% CI 2 to 18; p=0.002) in per-protocol; in both analyses, the upper CI bound exceeded 5.05 mg, and non-inferiority was not met. Individual 24-hour and 12-hour IV-MME favored TPVB; rescue analgesia was more frequent with ITM (21/36 vs 12/36; p=0.033). Pain outcomes, quality of recovery scores, and time to first opioid demand were similar, with no respiratory depression. Although mild 30-day Clavien-Dindo grade I events differed between groups, no apparent clinically meaningful safety signal was observed. CONCLUSIONS: ITM did not demonstrate non-inferiority to TPVB for 24-hour IV-MME; TPVB was associated with lower systemic opioid use, while pain outcomes were similar. TRIAL REGISTRATION NUMBER: NCT07126483.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Kaya C, Demirkol K, Sener EB, et al. Comparison of intrathecal morphine versus thoracic paravertebral block for video-assisted thoracoscopic surgery: a randomized non-inferiority trial. Reg Anesth Pain Med. 2026. PMID: 42309548. doi:10.1136/rapm-2026-107927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。